OSTEOTECH GRAFTON DRIVES REVENUE GROWTH IN 1997 WITH 74% U.S. SALES INCREASE; KENSEY NASH BREAKS EVEN ON ANGIO-SEAL ROYALTY STREAM IN SECOND QUARTER
This article was originally published in The Gray Sheet
A 74% domestic sales increase for Osteotech's flagship Grafton demineralized bone matrix product in 1997 to $34.9 mil. led the company to a solid financial performance in the three and 12-month periods ended Dec. 31., as revenues increased 34% to $12.2 mil. and 28% to $36 mil. for the quarter and year, respectively.
You may also be interested in...
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.